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Background: Renal cell carcinoma (RCC) is characterized by inherent resistance to chemotherapy. Earlier studies
demonstrated that microRNAs (miRNAs) might be involved in the chemosensitivity of cancers. MicroRNA let-7,
a putative tumor suppressor, is dysregulated in many cancers. Our study aims to investigate the exact role of let-7
in chemotherapy sensitivity of 5-fluorouracil (5-FU) in RCC.
Methods: The clinical significance of let-7b and let-7c expression in surgically resected specimens was assessed by
qRT-PCR. Cell proliferation assay and colony formation assay were used to assess the survival of 786-O cells treated
with let-7b or let-7c combined with 5-FU. Western blot was used to detect the expression of Akt2 and caspase-7.
Luciferase assay was used to detect the direct binding of let-7b and let-7c to the 3′-untranslated region (UTR)
of Akt2.
Results: Expression of let-7b and let-7c was significantly decreased in 32 paired clear cell renal cell carcinoma tissue
specimens and the dysregulation of let-7b was associated with pathological grade. Transfection of let-7b or let-7c
combined with 5-FU inhibited proliferation and potentiated the antitumor efficacies of 5-FU at tolerated concentration.
let-7b and let-7c suppressed the luciferase activity of reporter plasmid containing the 3′-UTR of Akt2. Overexpression
of let-7b and let-7c reduced Akt2 expression, and Akt2 inhibition enhanced the sensitivity to 5-FU by affecting
apoptotic pathway.
Conclusions: Expression of let-7b and let-7c was frequently decreased in clear cell renal cell carcinoma tissues. The
dysregulation of let-7b and let-7c may be involved in chemoresistance of RCC cells to 5-FU by down-regulating Akt2.
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Renal cell carcinoma (RCC) is the most lethal of the
common urologic cancers and accounts for 2% to 3% of
all adult malignant neoplasms. Approximately 30,000
new diagnoses of RCC are made each year in the United
States, and 12,000 patients die of disease [1]. Surgical re-
section of the primary tumor for patients with localized
disease remains the mainstay of therapy. However, a
high proportion of patients with metastases at diagnosis
or relapse following nephrectomy have a poor outcome
due to its resistance to chemotherapy and radiotherapy,
as it is widely accepted that RCC is among the most* Correspondence: jief67@sina.com
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unless otherwise stated.chemoresistant tumors [2]. The intrinsic drug resistance
in RCC, always impairing the efficiency of chemotherapy,
has been ascribed to the overexpression of multiple-drug
resistance protein (P-glycoprotein) and multiple-drug
resistance-associated protein 1 (MRP1) in 80% to 100% of
RCC tumors [3]. Targeted therapies can offer significant
clinical benefit, but rarely complete responses and de-
velopment of resistance after a median of 5 to 11 months
still remain a palliative treatment with a tremendous in-
crease in the cost of care [4]. Traditional anticancer drug
5-fluorouracil (5-FU) is widely used in the treatment of a
range of cancers. In RCC, rare response remains a signifi-
cant limitation to the clinical use of 5-FU, although trials
have indicated that responding patients survive longer [5].
Thus, it is of great significance to uncover the mecha-
nisms of insensitivity of RCC to 5-FU and then find a way
to re-sensitize RCC to anticancer drugs.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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noncoding RNAs, generally involved in posttranscriptional
gene regulation by binding to the 3′-untranslated region
(UTR) of target mRNAs. Dysregulation of miRNAs occurs
in various human cancers, and it is associated with the
biological properties of cancers [6]. We have previously
reported that miRNA let-7 acted as a tumor suppressor in
RCC cell lines by down-regulating C-myc and C-myc tar-
get genes [7]. let-7 is also involved in the drug resistance.
Enforced let-7 expression in hepatoma cancer sensitized
cells to 5-FU by targeting cyclin A [8]. let-7 also affected
sensitivity to tamoxifen treatment by targeting estrogen
receptor-α signaling in breast cancer [9]. However, the
role of let-7 in modulating the chemosensitivity of RCC is
still largely unknown.
The serine/threonine kinase Akt plays a crucial role in
cellular signaling pathway. In mammals, three isoforms
of the Akt family have been identified, termed Akt1,
Akt2, and Akt3, respectively [10]. AKT2 has been shown
to be linked to aggression and drug resistance in a variety
of human cancers, including ovarian cancer, breast cancer,
endometrial cancer, and malignant gliomas [11-13]. Down-
regulation of AKT2 sensitizes cancer cells to anticancer
drugs by affecting apoptosis pathway such as caspases-3,
caspases-6, caspases-9, PARP and p38 activity, and che-
moresistance proteins such as MDR1 and MRP1 [11-13].
Akt2 has been implicated as the downstream of let-7 [14].
Therefore, we hypothesized that there is an association of
Akt2 with let-7 in the resistance of RCC to anticancer
drugs.
In the present study, we investigated the expression of
let-7 in RCC tissues and found that the let-7b and let-7c
were significantly down-regulated in renal tumors com-
pared with normal tissues. We demonstrated for the first
time that let-7b and let-7c could affect the sensitivity of
RCC to 5-FU by targeting Akt2, which could reverse
RCC’s intrinsic resistance to chemotherapy and enhance
the effectiveness of anticancer drugs.
Methods
Clinical specimens from RCC patients
Thirty-two paired tissues were obtained from patients
who underwent radical nephrectomy at the department
of Urology, Shanghai First People’s Hospital, School of
Medicine, Shanghai Jiaotong University from August
2012 to December 2013. The specimens were collected
from normal region (outside the range of tumor at least
5 cm macroscopically) and tumor for each patient. All
the specimens were stored at −80°C immediately after sur-
gery until RNA extraction. The histological diagnosis was
confirmed by examining hematoxylin and eosin (H & E)-
stained original sections, simultaneously by two patho-
logists. Tumor stage was determined according to the
American Joint Committee on Cancer (AJCC), and nucleargrading was classified according to the method described
by Fuhrman et al. [15]. All patients were informed, and
consent was given.
Cell culture and transfection
The human RCC cell lines 786-O and 769-P were
obtained from the American Type Culture Collection
(ATCC) and cultured in RPMI 1640 medium (GIBCO,
Grand Island, NY, USA) supplemented with 10% fetal bo-
vine serum (GIBCO, Newcastle, Australia). The cells were
incubated at 37°C in a humid atmosphere with 5% CO2.
let-7b mimics, let-7c mimics, Akt2 siRNA, and the nega-
tive control were synthesized by Shanghai GenePharma
Co. 786-O and 769-P cells seeded at 1 × 105 cells/well in
6-well plates were transfected with let-7b or let-7c mimics
or the negative control using Lipofectamine 2000 Trans-
fection Reagent (Invitrogen, New York, NY, USA) at
50 nmol/l according to the manufacturer’s instruction.
The information of microRNA and siRNA sequences is
provided in Additional file 1.
Cell proliferation analysis and colony formation assay
Cell viability was determined by CCK-8 (Dojindo
Laboratories, Kumamoto, Japan) assay. 5-FU was pur-
chased from QiLu Pharmaceutical (Jinan, China). 786-O
cells were transfected with let-7b mimics, let-7c mimics,
Akt2 siRNA, or negative control for 24 h before seeded
into 96-well plates at 1,000 cells per well. For 5-FU treat-
ment, 1-104 μmol/l 5-FU was added into the growth
medium after seeded overnight. At certain time points,
the cells were incubated in CCK-8 in growth medium at
37°C for 4 h according to the manufacturer’s instruction.
The absorbance in each well was measured at 450 nm
using a microplate reader. For the colony formation assay,
transfected 786-O cells were seeded into 6-well plates at
1,000 cells per well with growth medium containing dif-
ferent concentrations of 5-FU. The medium containing
5-FU was replaced every 3 days until the visible colonies
formed. The colonies were fixed with 4% paraformalde-
hyde (Sigma-Aldrich Co., St. Louis, MO, USA) and stained
with 0.1% crystal violet (Sigma-Aldrich Co., St. Louis, MO,
USA). Colonies >50 μm in diameter were counted.
Western blot analysis
The Western blot analysis was performed as described
earlier [16]. Briefly, proteins were harvested for Western
blot analysis 48 h after transfection. After denatured at
100°C for 5 min, samples were separated (30 μg per lane)
on 10% SDS-PAGE (Bio-Rad Laboratories, Hercules, CA,
USA) and then transferred onto a polyvinylidene di-
fluoride membrane (Roche Applied Science, Mannheim,
Germany). The membrane was blocked with 5% skim milk
at room temperature for 1 h, incubated overnight at 4°C
with Akt2 antibody (abcam, Cambridge, UK) and caspase-
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cubated with anti-rabbit IgG secondary antibody (Cell
Signaling Technology, MA). A β-Actin antibody was used
to determine loading (Cell Signaling Technology, Danvers,
MA, USA). Antibody binding was visualized by chemilu-
minescence (Boster Company, Wuhan, China).
Luciferase assay
The Akt2 3′-UTR and control vectors were purchased
from GeneCopoeia. 786-O cells were transiently trans-
fected with Akt2 3′-UTR reporter plasmid or control vec-
tor and let-7b or let-7c mimics or negative control. Firefly
luciferase activities were measured by using the Dual
Luciferase Reporter assay system (Promega, Madison, WI,
USA) 36 h after transfection. The results were normalized
with Renilla luciferase.
Total RNA extraction, reverse transcription, and qRT-PCR
Total RNA from tissues was extracted using the TRizol
reagent (Invitrogen, Carslbad, CA, USA) as described
previously [7]. Reverse transcription for miRNAs was
performed using Universal cDNA Synthesis Kit (Exiqon,
Vedbaek, Denmark) according to the manufacturer’s
instruction. Primer sets for real-time PCR of let-7b-5p,
let-7c-5p, and 5S rRNA were purchased from Exiqon. The
SYBR Green Master Mix was from Applied Biosystems
(Carlsbad, CA, USA). The ABI 7900 HT Sequence Detec-
tion System (Applied Biosystems, Carlsbad, CA, USA, and
Life Technologies, Carslbad, CA, USA) was used for
quantitative real-time PCR assay. 5S rRNA was used for
normalization. The information of primer sequences is
provided in Additional file 1.
Statistical analysis
All statistical analyses were performed with SAS 8.0, and
values were presented as mean ± SD from at least three
separate experiments. The levels of let-7b and let-7c bet-
ween the normal and RCC tissues were compared by
Wilcoxon signed rank sum test. The relationship bet-
ween let-7b and let-7c expression was analyzed by the
Spearman rank correlation. Differences between the ex-
pression of let-7b or let-7c and clinicopathological features
were assessed by χ2 test. Student’s t-test was used to eva-
luate the significance of inter-group differences. Values
with P < 0.05 were considered statistically significant.
Results
Down-regulation of let-7b and let-7c in RCC tissues
To explore whether let-7 was dysregulated in RCC, qRT-
PCR analysis was used to determine the expression levels
of let-7 family (let-7a, let-7b, let-7c, let-7d, let-7e, let-7f
and let-7 g) in 32 pairs of RCC and adjacent normal kid-
ney tissues. The median age at diagnosis was 61 (range 40to 93) years old. The clinical and pathologic characteristics
of the patients were shown in Table 1.
In RCC tissues, let-7b and let-7c expression levels were
the most significantly decreased compared to correspon-
ding normal tissues (P < 0.05, Figure 1A). Thus, we chose
these two miRNAs for further study. The Spearman rank
test showed a positive correlation between let-7b and
let-7c expression (r = 0.810, P < 0.05, Figure 1B). Then, we
analyzed the data to see if any correlation exists between
the expression of miRNAs and clinical characteristics.
In patients with more advanced histopathological grade
tumors, let-7b levels were significantly down-regulated
(P < 0.05, Table 1).let-7b and let-7c enhanced the antitumor efficacies
of 5-FU
We previously noted that let-7 could inhibit proliferation of
RCC cell lines [7]. We also wondered whether the inhibi-
tory effect could be enhanced when combined with 5-FU
treatment. For this purpose, let-7b or let-7c were trans-
fected into 786-O cells, and then, the cells were treated
with different doses of 5-FU. The CCK-8 assay showed
that let-7b and let-7c transfected cells were more sensitive
to 5-FU than control cells (P < 0.05, Figure 2). 5-FU mo-
notherapy also showed antitumor effect, and the effect in-
creased with the increasing concentrations. Similarly,
colony formation assay showed that, in the condition of
the same dose of 5-FU, transfected cells grew more slowly
than control cells (P < 0.05, Figure 3). Thus, enforced ex-
pression of let- 7b and let-7c restored chemosensitivity to
5-FU in RCC cells, which suggests that co-treatment
would reduce the dose of chemotherapy and reduce the
side effect caused by 5-FU.Akt2 was a target of let-7b and let-7c
To explore the mechanism of let-7b and let-7c mediated
chemosensitivity, we hypothesized that let-7b and let-7c
may inhibit proliferation of 5-FU-treated cells through
down-regulation of Akt2. Firstly, Targetscan and miR-
Base database showed that Akt2 is a potential target of
let-7 (Figure 4A), and also, Akt2 was a putative let-7 tar-
get in previous findings [14]. In addition, recent studies
have shown that down-regulation of Akt2 expression ap-
peared to sensitize cancer cells to typical chemothera-
peutic agents [11-13]. We transfected 786-O and 769-P
cells with let-7b and let-7c mimics or negative control.
Forty-eight hours after transfection, Western blot ana-
lysis showed that the cells transfected with let-7b and
let-7c mimics displayed decreased expression of Akt2
(Figure 4B). Furthermore, transfection of 786-O cells
with Akt2 3′-UTR plasmid along with let-7b or let-7c
led to a significant decrease in relative luciferase units
when compared with empty vector or negative control
Table 1 Patient characteristics and clinicopathological factors by let-7 expression
Variables Number of
patients (%)
let-7b expression let-7c expression
Low High P value Low High P value
Gender
Male 24 (0.75) 19 5 0.3458 19 5 0.8050
Female 8 (0.25) 5 3 6 2
Age(years)
>65 12 (0.37) 9 3 1.0000 9 3 0.7405
≤65 20 (0.63) 15 5 16 4
Tumor size(cm)
>4 15 (0.47) 12 3 0.5395 10 5 0.1408
≤4 17 (0.53) 12 5 15 2
Pathologic stage
pT1 to T2 24 (0.75) 16 8 0.0593 17 7 0.0840
pT3 to T4 8 (0.25) 8 0 8 0
Lymph node involvement
N0 31 (0.97) 23 8 0.5575 24 7 0.5908
N1 to N2 1 (0.03) 1 0 1 0
Grade
I to II 23 (0.72) 15 8 0.0411 17 6 0.3569
III to IV 9 (0.28) 9 0 8 1
Figure 1 Expression of let-7b and let-7c in the 32 paired clinical specimens. (A) Expression of let-7b and let-7c was lower in 32 RCC clinical specimens
than in 32 normal kidney specimens (P < 0.05). (B) let-7b and let-7c expression correlated positively (r = 0.810, P < 0.05).
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Figure 2 CCK-8 assay showed that let-7b and let-7c enhanced chemosensitivity of 786-O cells to 5-FU. (A) Relative cell survival of 786-O cells at
certain time points (24, 48, 60, and 72 h) after transfected with let-7b or let-7c mimics and treated with 5-FU at progressive concentrations (1, 10,
102, 103, and 104 μmol/l). (B) Relative cell survival of different groups with previous treatment for 24, 48, 60, and 72 h, in which 5-FU is at concentrations
of 10 and 102 μmol/l. Cell viability assay showed the inhibition of 786-O cells proliferation by transfection of let-7b and let-7c (*P < 0.05).
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direct target of let-7b and let-7c in renal cancer.
Akt2 inhibition enhanced the sensitivity to 5-FU through
apoptotic pathway
We further explore mechanisms of potential reversal of
chemoresistance through Akt inhibition. We initially tested
2 siRNAs to achieve 80% to 90% Akt2 gene knockdown
and confirmed the results by Western blot (Figure 5B).
Then, we selected one siRNA (si-Akt2#2) for further exper-
iments. Inhibition of Akt2 expression by siRNA enhanced
the sensitivity of renal cancer cells to 5-FU (Figure 5A).
Next, we found the knockdown of Akt2 increased the ex-
pression of the pro-apoptotic factor caspase-7, indicatingthat Akt2 contributes to the chemoresistance through
apoptotic pathway.
Discussion
Surgery is thought to achieve cure in localized RCC, but
for patients with recurrent or metastatic tumors, the
efficacy of systemic therapy (chemotherapy, immuno-
therapy, and targeted therapy) is often limited. Although
targeted therapy is highly recommended to improve sur-
vival, rarely complete responses and tremendous in-
crease of the cost limit its wide application. 5-FU is an
antimetabolite drug, which is the analogue of uracil with
a fluorine atom at the C-5 position in place of hydrogen
and enters cell as the same transport mechanism as
Figure 3 Colony formation assay was used to detect the cell growth activity. (A) Clones of transfected cells were less than control cells. The
antitumor effects of 5-FU in transfected cells were more profound than those in the control cells. (B) Relative colony numbers of transfected cells
and control cells. Less growth activity was found in transfected cells compared to control cells (*P < 0.05).
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been ascribed to the inhibition of thymidylate synthase
and incorporation of its metabolites into RNA and
DNA. 5-FU is widely used in the treatment of a range of
cancers, including colorectal, breast cancers, and head
and neck cancers. 5-FU-based chemotherapy improves
overall and disease-free survival of patients with above
cancers [17]. However, RCC is insensitive to 5-FU, and it
achieves response rates in the range of 5% to 8%. Clini-
cally, 5-FU-based chemotherapy is considered mode-
rately effective in RCC patients due to rare response and
5-FU-related severe toxicity [5,18]. Molecular mechanisms
leading to 5-FU chemoresistance are poorly understood,
thus factors that enhance the sensitivity of RCC cells to
5-FU may highlight predictive biomarkers or targets for
therapy.
miRNAs have been proved to participate in the bio-
logical behavior of cancers as either tumor suppressors
or oncogenes. Many studies, including our own, have re-
ported that let-7 acts as a tumor suppressor in RCC
[7,19]. Consistent with recently published reports that
let-7 family was dysregulated in several types of human
cancer, we found that let-7b and let-7c were down-
regulated in RCC tissues compared with normal samples.
Furthermore, our study revealed that decreased expression
of let-7b was associated with grade in RCC, indicating that
loss of this miRNA may be an early event in renal carcino-
genesis and contribute to its intrinsic chemoresistance.
Chemoresistance represents a limiting factor for suc-
cessful cancer therapy. It is of great benefit for opti-
mizing cancer treatment to elucidate the mechanism ofchemoresistance and identify the markers predicting the
response to anticancer drugs. A few studies have re-
ported the role of miRNAs in regulating sensitivity of
cancer cells to chemotherapy. Boyerinas et al. [20] col-
lected 20 patients with epithelial ovarian cancer who had
received chemotherapy with Taxol and carboplatin and
demonstrated that the expression of let-7d was significantly
reduced in patients with recurrence after chemotherapy.
Up-regulation of let-7g expression renders the cells more
sensitive to treatment with either Taxol or vinblastine, by
targeting IMP-1, resulting in destabilization of the mRNA
of MDR1, which is a member of the adenosine tri-
phosphate binding cassette transporters (ABC transporter
family) that act by pumping drugs across the cell membrane
to the extracellular space and known to affect treatment
outcome by conferring intrinsic or acquired resistance to
a variety of drugs. Another study by Sugimura et al. [21],
which measured the expression of several miRNAs in
biopsy samples from 98 patients with esophageal cancer
who received preoperative chemotherapy, showed that
low expression of let-7b and let-7c correlated significantly
with poor response to chemotherapy, both clinically and
histopathologically. In vitro assay showed that transfection
of let-7c restored sensitivity to cisplatin through directly
repressing interleukin (IL)-6/STAT3 pro-survival pathway.
Here, we show that, besides the growth inhibition, let-7b
and let-7c could also enhance the cytotoxicities of 5-FU to
RCC, which is inherent resistant to anticancer drugs, and
partially through down-regulation of Akt2.
Akt2 is a member of Akt family, which is an inactive
cytosolic serine/threonine kinase activated by a phospha-
Figure 4 Akt2 is a functional target of let-7b and let-7c. (A) Schematic
representation of Akt2 3′-UTRs as the putative target of let-7b and
let-7c. (B) Western blot analysis demonstrated significant decreased
expression of Akt2 in transfected cells. (C) Luciferase assay showed
decreased reporter activity after co-transfection of Akt2 3′-UTR plasmid
with let-7b or let-7c in 786-O cells (*P < 0.05).
Figure 5 Knockdown of Akt2 enhanced the chemosensitivity through casp
Akt2 siRNA and treated with 5-FU. Proliferation of 786-O cells after transfection
(*P < 0.05). (B) Akt2 and caspase-7 protein levels were assessed by Western bl
Akt2 knockdown showed the increased expression of caspase-7.
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and plays a crucial role in cellular signaling pathway, regu-
lating cell growth, differentiation, survival, and metabo-
lism [10,22,23]. Previous studies indicated that Akt2 is
associated with resistance to chemotherapy in a variety of
malignancies. In breast cancer, Cheng et al. [24] demon-
strated that Akt2 is transcriptionally up-regulated by twist
leading to resistance to paclitaxel. Weng et al. [25] re-
ported that Akt2 protects human ovarian cancer cells
from docetaxel and paclitaxel-induced apoptosis via the
p38 pathway and survivin expression. Girouard et al. [12]
demonstrated that Akt2 down-regulation in endometrial
cancer cells sensitizes cells to cisplatin by inducing the
activation of pro-apoptotic factors such as the cleavage of
caspases-3, −6, −9, and PARP. With regard to RCC, one
recent study, which evaluated Akt activation by immuno-
histochemistry in 48 RCC biopsies, showed that elevated
Akt activation could be a common finding and thus sug-
gested that Akt might have an important role in the
pathogenesis and progression of renal cell carcinoma [26].
Moreover, Sourbier et al. [27] found that inhibition of Akt
phosphorylation induced cell apoptosis, thus indicating
that activation of the Akt pathway in renal cell carcinoma
might be one of the resistance mechanisms. Akt2 is
thought to be a putative let-7 target in previous findings,
but this is the first time to show that the association bet-
ween let-7 and Akt2 plays an important role in the
sensitivity to chemotherapy for RCC. Akt2 knockdown
showed the same inhibition and increased expression
of pro-apoptotic factor caspase-7, implying a functional
interaction between Akt2 and the apoptotic pathway.
These results suggest that treatment targeting this path-
way is likely to enhance the sensitivity to chemotherapy.
In addition, further research is needed to investigate
whether the antitumor effect of other chemotherapeutic
regimens could be enhanced by let-7 and the clinical
use of let-7 combined with chemotherapy in patients
with RCC.ase-7. (A) Relative cell survival of 786-O cells 48 h after transfected with
of Akt2 siRNA was significantly reduced compared with negative control
ot in 786-O cells transfected with si-Akt2 (#1, #2) and negative control.
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In conclusion, the results of the present study demon-
strated that let-7b and let-7c were frequently down-
regulated in RCC clinical specimens and dysregulation
of let-7 may involve in chemoresistance of RCC cells to
5-FU. Moreover, the results also showed that the effect
of let-7 expression on chemosensitivity is mediated
though down-regulation of Akt2, further affecting pro-
apoptotic factor caspase-7. This finding suggests that
let-7 applied with tolerated concentration of 5-FU may
be a potential therapeutic strategy for RCC therapy.
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this study.
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